161 related articles for article (PubMed ID: 16417732)
41. Ovarian morphology and endocrine function in polycystic ovary syndrome.
Tena G; Moran C; Romero R; Moran S
Arch Gynecol Obstet; 2011 Dec; 284(6):1443-8. PubMed ID: 21243502
[TBL] [Abstract][Full Text] [Related]
42. Polycystic ovary morphology is associated with insulin resistance in women with polycystic ovary syndrome.
Hong SH; Sung YA; Hong YS; Jeong K; Chung H; Lee H
Clin Endocrinol (Oxf); 2017 Oct; 87(4):375-380. PubMed ID: 28543550
[TBL] [Abstract][Full Text] [Related]
43. The effect of drospirenone (3 mg) with ethinyl estradiol (30 mcg) containing pills on ovarian blood flows in women with polycystic ovary syndrome: a case controlled study.
Okyay E; Gode F; Acet F; Bodur T; Cagliyan E; Sahan C; Posaci C; Gulekli B
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():93-9. PubMed ID: 25063905
[TBL] [Abstract][Full Text] [Related]
44. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria.
Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T
Arch Gynecol Obstet; 2016 Feb; 293(2):447-56. PubMed ID: 26408006
[TBL] [Abstract][Full Text] [Related]
45. Revised criteria for PCOS in WHO Group II anovulatory infertility - a revival of hypothalamic amenorrhoea?
Lauritsen MP; Pinborg A; Loft A; Petersen JH; Mikkelsen AL; Bjerge MR; Nyboe Andersen A
Clin Endocrinol (Oxf); 2015 Apr; 82(4):584-91. PubMed ID: 25262871
[TBL] [Abstract][Full Text] [Related]
46. Lack of linear relationship between hyperinsulinaemia and hyperandrogenism.
Toscano V; Bianchi P; Balducci R; Guglielmi R; Mangiantini A; Lubrano C; Sciarra F
Clin Endocrinol (Oxf); 1992 Feb; 36(2):197-202. PubMed ID: 1533185
[TBL] [Abstract][Full Text] [Related]
47. Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome?
Cibula D; Hill M; Fanta M; Sindelka G; Zivny J
Hum Reprod; 2001 May; 16(5):940-4. PubMed ID: 11331641
[TBL] [Abstract][Full Text] [Related]
48. Absent biologically relevant associations between serum inhibin B concentrations and characteristics of polycystic ovary syndrome in normogonadotrophic anovulatory infertility.
Laven JS; Imani B; Eijkemans MJ; de Jong FH; Fauser BC
Hum Reprod; 2001 Jul; 16(7):1359-64. PubMed ID: 11425813
[TBL] [Abstract][Full Text] [Related]
49. Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots.
Barth JH; Field HP; Yasmin E; Balen AH
Eur J Endocrinol; 2010 Mar; 162(3):611-5. PubMed ID: 20008514
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome.
Hahn S; Kuehnel W; Tan S; Kramer K; Schmidt M; Roesler S; Kimmig R; Mann K; Janssen OE
Clin Chem Lab Med; 2007; 45(2):202-7. PubMed ID: 17311509
[TBL] [Abstract][Full Text] [Related]
51. Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome.
Ezeh U; Huang A; Landay M; Azziz R
J Womens Health (Larchmt); 2018 Jul; 27(7):892-902. PubMed ID: 29878857
[TBL] [Abstract][Full Text] [Related]
52. [Clinical, hormonal and metabolic characteristics of different phenotypes of polycystic ovary syndrome, in Bulgarian population].
Kavardzhikova S; Pechlivanov B
Akush Ginekol (Sofiia); 2010; 49(4):32-7. PubMed ID: 20734639
[TBL] [Abstract][Full Text] [Related]
53. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome.
Fraissinet A; Robin G; Pigny P; Lefebvre T; Catteau-Jonard S; Dewailly D
Hum Reprod; 2017 Aug; 32(8):1716-1722. PubMed ID: 28854589
[TBL] [Abstract][Full Text] [Related]
54. Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls.
Panidis D; Farmakiotis D; Koliakos G; Rousso D; Kourtis A; Katsikis I; Asteriadis C; Karayannis V; Diamanti-Kandarakis E
Hum Reprod; 2005 Aug; 20(8):2127-32. PubMed ID: 15890737
[TBL] [Abstract][Full Text] [Related]
55. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
White D; Leigh A; Wilson C; Donaldson A; Franks S
Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
[TBL] [Abstract][Full Text] [Related]
56. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients.
Balen AH; Conway GS; Kaltsas G; Techatrasak K; Manning PJ; West C; Jacobs HS
Hum Reprod; 1995 Aug; 10(8):2107-11. PubMed ID: 8567849
[TBL] [Abstract][Full Text] [Related]
57. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume.
Lujan ME; Jarrett BY; Brooks ED; Reines JK; Peppin AK; Muhn N; Haider E; Pierson RA; Chizen DR
Hum Reprod; 2013 May; 28(5):1361-8. PubMed ID: 23503943
[TBL] [Abstract][Full Text] [Related]
58. Successive and cyclic oral contraceptive pill pretreatment improves IVF/ICSI outcomes of PCOS patients and ameliorates hyperandrogenism and antral follicle excess.
Pan JX; Liu Y; Ke ZH; Zhou CL; Meng Q; Ding GL; Xu GF; Sheng JZ; Huang HF
Gynecol Endocrinol; 2015 Apr; 31(4):332-6. PubMed ID: 25558892
[TBL] [Abstract][Full Text] [Related]
59. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne.
Timpatanapong P; Rojanasakul A
J Dermatol; 1997 Apr; 24(4):223-9. PubMed ID: 9164062
[TBL] [Abstract][Full Text] [Related]
60. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.
Suikkari AM; Tiitinen A; Stenman UH; Seppälä M; Laatikainen T
Fertil Steril; 1991 May; 55(5):895-9. PubMed ID: 1708731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
